OBJECTIVE: The aim of the study was to evaluate the effect of the angiotensin receptor blocker eprosartan on pulse pressure as well as to identify those factors influencing such effect. METHODS: Observational, multicenter study performed in hypertensive patients attending primary care centers. Patients completed 12 weeks of treatment with eprosartan. Blood pressure was measured by means of a validated oscillometric device (OMRON 705CP) provided with a printer at beginning of treatment and at 4, 8 and 16 weeks. RESULTS: After 16 weeks, 3133 patients out of 4067completed treatment (87 % in monotherpy), mean age of 67 years (55% women). Components of blood pressure decreased: systolic blood pressure from 165.9 ± 15.5 mm Hg dyastolic from 93.5 ± 10.4 to 80.6 ± 8.3 mmHg, mean blood pressure from 117 ± 9.3 mmHg to 100.1 ± 9.0 3 mmHg, pulse pressure from 72.5 ± 16.9 mmHg, PP decrease at 16th week was 4% higher to the decrease in MBP. The effect was more pronounced in older patients, those with higher basal PP/MBP and with target organ damage. Among adverse events reported, 35 % affected to digestive system. CONCLUSIONS: Eprosartan is an effective and well tolerated antihypertensive drug able to reduce PP. This reduction is partially independent of the severity of high blood pressure. This aspect may be important in terms of safety and target organ protection.